Physician profile
Sameh Z Lamiy
NPI 1952375537
$5,935.28
in general payments reported to CMS, 2019-2025
27 companies · $383 in 2025
The $383 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,963 · 2020: $112 · 2021: $138 · 2022: $246 · 2023: $544 · 2024: $2,549 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767 · Travel and Lodging: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.20 |
| Travel and Lodging | $1,708.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,884.01 | 2024 | Evera Mri Xt Dr Surescan |
| Medtronic Vascular, INC. | $967.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $542.20 | 2019-2024 | |
| Biosense Webster, INC. | $486.82 | 2019-2025 | Carto 3 |
| Abbott Laboratories | $423.60 | 2019-2025 | Ensite, Aveir |
| Boston Scientific Corporation | $381.83 | 2021-2024 | Lux-Dx Insertable Cardiac Monitor, Sq-Rx Pulse Generator |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $318.51 | 2019-2024 | Lifevest |
| Amgen INC. | $118.55 | 2019-2023 | Repatha |
| Cardiva Medical, INC. | $100.31 | 2021-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Pfizer INC. | $94.73 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $91.41 | 2019-2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $59.29 | 2023-2024 | Verquvo, Winrevair |
| Philips North America LLC | $54.42 | 2022-2023 | |
| Lundbeck LLC | $49.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $48.88 | 2022-2023 | Camzyos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.70 | 2019-2022 | |
| Novo Nordisk INC | $41.65 | 2023-2024 | Wegovy |
| Kestra Medical Technology Services, INC. | $32.55 | 2024 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $31.47 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.68 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.78 | 2019-2022 | |
| Innovation Technologies INC | $24.94 | 2025 | Irrisept |
| Altathera Pharmaceuticals LLC | $19.73 | 2022 | |
| Angiodynamics, INC. | $18.56 | 2021 | |
| Abiomed | $15.97 | 2019 | |
| Terumo Medical Corporation | $14.77 | 2023 | Azur Cx Detachable, Glidewire, Optitorque |
| Janssen Pharmaceuticals, INC | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameh Lamiy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.